{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:07:30Z","timestamp":1793326050577,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C1094530"],"award-info":[{"award-number":["2021R1A2C1094530"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00209741"],"award-info":[{"award-number":["RS-2023-00209741"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008005","name":"Yonsei University | Yonsei University College of Medicine","doi-asserted-by":"publisher","award":["6-2019-0187"],"award-info":[{"award-number":["6-2019-0187"]}],"id":[{"id":"10.13039\/501100008005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to determine the activity of the anti-VEGF receptor tyrosine-kinase inhibitor, pazopanib, combined with the anti-PD-L1 inhibitor, durvalumab, in metastatic and\/or recurrent soft tissue sarcoma (STS). In this single-arm phase 2 trial (NCT03798106), treatment consisted of pazopanib 800\u2009mg orally once a day and durvalumab 1500\u2009mg once every 3 weeks. Primary outcome was overall response rate (ORR) and secondary outcomes included progression-free survival (PFS), overall survival, disease control rate, immune-related response criteria, and safety. The ORR was 30.4% and the trial met the pre-specified endpoint. The median PFS was 7.7 months (95% confidence interval: 5.7\u201310.4). The common treatment-related adverse events of grades 3\u20134 included neutropenia (9 [19.1%]), elevated aspartate aminotransferase (7 [14.9%]), alanine aminotransferase (5 [10.6%]), and thrombocytopenia (4 [8.5%]). In a prespecified transcriptomic analysis, the B lineage signature was a significant key determinant of overall response (<jats:italic>P<\/jats:italic>\u2009=\u20090.014). In situ analysis also showed that tumours with high CD20<jats:sup>+<\/jats:sup> B cell infiltration and vessel density had a longer PFS (<jats:italic>P<\/jats:italic>\u2009=\u20096.5 \u00d7 10<jats:sup>\u22124<\/jats:sup>) than those with low B cell infiltration and vessel density, as well as better response <jats:bold>(<\/jats:bold>50% <jats:italic>vs<\/jats:italic> 12%, <jats:italic>P<\/jats:italic>\u2009=\u20090.019). CD20<jats:sup>+<\/jats:sup> B cell infiltration was identified as the only independent predictor of PFS via multivariate analysis. Durvalumab combined with pazopanib demonstrated promising efficacy in an unselected STS cohort, with a manageable toxicity profile.<\/jats:p>","DOI":"10.1038\/s41467-024-44875-2","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T15:02:18Z","timestamp":1706022138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Hee Jin","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5268-3191","authenticated-orcid":false,"given":"Kum-Hee","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3878-1944","authenticated-orcid":false,"given":"Seung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6638-4110","authenticated-orcid":false,"given":"Wooyeol","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Dae","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyum","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyang Joo","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iksung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0412-8709","authenticated-orcid":false,"given":"Heounjeong","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3780-3213","authenticated-orcid":false,"given":"Inkyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0625-9828","authenticated-orcid":false,"given":"Hyo Song","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"44875_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson, I. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15, 415\u2013423 (2014).","journal-title":"Lancet Oncol."},{"key":"44875_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"S Sleijfer","year":"2010","unstructured":"Sleijfer, S. et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur. J. Cancer 46, 72\u201383 (2010).","journal-title":"Eur. J. Cancer"},{"key":"44875_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon, B. et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 18, 1397\u20131410 (2017).","journal-title":"Lancet Oncol."},{"key":"44875_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri, G. D. et al. Efficacy and safety of Trabectedin or Dacarbazine for metastatic Liposarcoma or Leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III randomized multicenter clinical trial. J. Clin. Oncol. 34, 786\u2013793 (2016).","journal-title":"J. Clin. Oncol."},{"key":"44875_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1634\/theoncologist.12-8-999","volume":"12","author":"RG Maki","year":"2007","unstructured":"Maki, R. G. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist 12, 999\u20131006 (2007).","journal-title":"Oncologist"},{"key":"44875_CR6","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Schoffski","year":"2016","unstructured":"Schoffski, P. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629\u20131637 (2016).","journal-title":"Lancet"},{"key":"44875_CR7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879\u20131886 (2012).","journal-title":"Lancet"},{"key":"44875_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo, S. P. et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 19, 416\u2013426 (2018).","journal-title":"Lancet Oncol."},{"key":"44875_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493\u20131501 (2017).","journal-title":"Lancet Oncol."},{"key":"44875_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang, J., Yan, J. & Liu, B. Targeting VEGF\/VEGFR to modulate antitumor immunity. Front. Immunol. 9, 978 (2018).","journal-title":"Front. Immunol."},{"key":"44875_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi, F. S. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632\u2013642 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"44875_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"44875_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","volume":"20","author":"BA Wilky","year":"2019","unstructured":"Wilky, B. A. et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 20, 837\u2013848 (2019).","journal-title":"Lancet Oncol."},{"key":"44875_CR14","doi-asserted-by":"publisher","first-page":"e001561","DOI":"10.1136\/jitc-2020-001561","volume":"8","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto, J. et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial. J. Immunother. Cancer 8, e001561 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"44875_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44\u201356 (2019).","journal-title":"Ann. Oncol."},{"key":"44875_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","volume":"11","author":"M Montesion","year":"2021","unstructured":"Montesion, M. et al. Somatic HLA Class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response. Cancer Discov. 11, 282\u2013292 (2021).","journal-title":"Cancer Discov."},{"key":"44875_CR17","doi-asserted-by":"publisher","first-page":"672677","DOI":"10.3389\/fonc.2021.672677","volume":"11","author":"P Wang","year":"2021","unstructured":"Wang, P., Chen, Y. & Wang, C. Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front. Oncol. 11, 672677 (2021).","journal-title":"Front. Oncol."},{"key":"44875_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 17, 218 (2016).","journal-title":"Genome Biol."},{"key":"44875_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"44875_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"44875_CR21","unstructured":"Penella Woll, P. G., Ian Judson, Michelle Scurr, Sandra Strauss, Beatrice Seddon, Michael Leahy, Maria Marples, Ana Hughes, Baljit Kaur, Cindy Billingham. Axi-STS: an NCRI Sarcoma Clinical Studies Group phase II trial of the VEGFR inhibitor axitinib in advanced soft tissue sarcoma (STS). in NCRI Cancer Conference (2014)."},{"key":"44875_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40268-017-0203-y","volume":"17","author":"P Grassi","year":"2017","unstructured":"Grassi, P. et al. Does dose modification affect efficacy of first-line Pazopanib in metastatic renal cell carcinoma? Drugs R. D. 17, 461\u2013467 (2017).","journal-title":"Drugs R. D."},{"key":"44875_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network.","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950\u2013965.e928 (2017).","journal-title":"Cell"},{"key":"44875_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4161\/onci.1.1.17825","volume":"1","author":"SW Sorbye","year":"2012","unstructured":"Sorbye, S. W. et al. High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncoimmunology 1, 75\u201377 (2012).","journal-title":"Oncoimmunology"},{"key":"44875_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6890-12-5","volume":"12","author":"SW Sorbye","year":"2012","unstructured":"Sorbye, S. W. et al. Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clin. Pathol. 12, 5 (2012).","journal-title":"BMC Clin. Pathol."},{"key":"44875_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2451-6","volume":"16","author":"C Kim","year":"2016","unstructured":"Kim, C. et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 16, 434 (2016).","journal-title":"BMC Cancer"},{"key":"44875_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672 (2021).","journal-title":"Ann. Oncol."},{"key":"44875_CR28","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.labinv.2023.100063","volume":"103","author":"L Vanhersecke","year":"2023","unstructured":"Vanhersecke, L. et al. Standardized pathology screening of mature tertiary lymphoid structures in cancers. Lab. Invest. 103, 100063 (2023).","journal-title":"Lab. Invest."},{"key":"44875_CR29","doi-asserted-by":"publisher","first-page":"e76386","DOI":"10.1371\/journal.pone.0076386","volume":"8","author":"J Dornbusch","year":"2013","unstructured":"Dornbusch, J. et al. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma. PLoS One 8, e76386 (2013).","journal-title":"PLoS One"},{"key":"44875_CR30","doi-asserted-by":"publisher","first-page":"e0153745","DOI":"10.1371\/journal.pone.0153745","volume":"11","author":"J Rautiola","year":"2016","unstructured":"Rautiola, J. et al. Association of Angiopoietin-2 and Ki-67 Expression with vascular density and sunitinib response in metastatic renal cell carcinoma. PLoS One 11, e0153745 (2016).","journal-title":"PLoS One"},{"key":"44875_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bju.15600","volume":"130","author":"SJ Welsh","year":"2022","unstructured":"Welsh, S. J. et al. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. BJU Int 130, 244\u2013253 (2022).","journal-title":"BJU Int"},{"key":"44875_CR32","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/carcin\/bgs222","volume":"33","author":"S Biswas","year":"2012","unstructured":"Biswas, S. et al. CD31 angiogenesis and combined expression of HIF-1alpha and HIF-2alpha are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFalpha transcriptional products are not: implications for antiangiogenic trials and HIFalpha biomarker studies in primary CC-RCC. Carcinogenesis 33, 1717\u20131725 (2012).","journal-title":"Carcinogenesis"},{"key":"44875_CR33","doi-asserted-by":"publisher","first-page":"djx066","DOI":"10.1093\/jnci\/djx066","volume":"109","author":"C Bais","year":"2017","unstructured":"Bais, C. et al. Tumor microvessel density as a potential predictive marker for Bevacizumab Benefit: GOG-0218 biomarker analyses. J. Natl. Cancer Inst. 109, djx066 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"44875_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde, M. et al. Use of PD-1 Targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A Phase 2 clinical trial. JAMA Oncol. 4, 93\u201397 (2018).","journal-title":"JAMA Oncol."},{"key":"44875_CR35","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","volume":"26","author":"EZ Keung","year":"2020","unstructured":"Keung, E. Z. et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to Pembrolizumab. Clin. Cancer Res. 26, 1258\u20131266 (2020).","journal-title":"Clin. Cancer Res."},{"key":"44875_CR36","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1002\/cncr.30738","volume":"123","author":"E Ben-Ami","year":"2017","unstructured":"Ben-Ami, E. et al. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer 123, 3285\u20133290 (2017).","journal-title":"Cancer"},{"key":"44875_CR37","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1002\/cncr.30726","volume":"123","author":"SM Pollack","year":"2017","unstructured":"Pollack, S. M. et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer 123, 3291\u20133304 (2017).","journal-title":"Cancer"},{"key":"44875_CR38","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","volume":"2","author":"MA Dickson","year":"2016","unstructured":"Dickson, M. A. et al. Progression-free survival among patients with well-differentiated or dedifferentiated Liposarcoma treated with CDK4 Inhibitor Palbociclib: A Phase 2 clinical trial. JAMA Oncol. 2, 937\u2013940 (2016).","journal-title":"JAMA Oncol."},{"key":"44875_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"44875_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4143\/crt.2022.251","volume":"55","author":"JY Hong","year":"2023","unstructured":"Hong, J. Y. et al. Comprehensive molecular characterization of soft tissue sarcoma for prediction of Pazopanib-based treatment response. Cancer Res. Treat. 55, 671\u2013683 (2023).","journal-title":"Cancer Res. Treat."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44875-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44875-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T15:02:40Z","timestamp":1706022160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44875-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44875"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-44875-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S.K. received grant\/research support from MSD, Eli Lilly and Company, Ono Pharmaceutical Company, Medpacto Pharmaceutical, and Boryung Pharmaceutical Company outside the submitted work. S.Y.R. received grant\/research support from MSD, Celltrion, Boehringer-Ingelheim, Eli Lilly and Company, Taiho, Bristol-Myers Squibb, ASLAN, and Incyte; consultation fees for Daiichi Sankyo, MSD, Eli Lilly, Bristol-Myers Squibb, and Eisail; and served on a speaker\u2019s bureau for Eli Lilly, Bristol-Myers Squibb, and MSD outside the submitted work. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"685"}}